Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistNuvo Life Health Inc. sold unapproved and misbranded compounded drugs, specifically semaglutide and tirzepatide, directly to consumers via their website in violation of the Federal Food, Drug, and Cosmetic Act. The company's marketing claims that their compounded products were "similar to" FDA-approved drugs like Ozempic, Wegovy, and Mounjaro were false and misleading, as compounded drugs lack FDA approval and cannot be represented as equivalent to approved medications. This marketing practice violated sections 502(a) and 502(bb) of the FDCA, which prohibit false or misleading labeling and advertising of compounded drugs.